Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. More is better: Combination therapies for myelodysplastic syndromes

    ... are currently three FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these ... and acceptable side-effect profiles. -Azacitidine and lenalidomide, two FDA approved drugs in MDS, have also been combined with ...

    Research Review last updated 05/02/2016 - 9:14am.

  2. New therapeutics for myelodysplastic syndromes

    ... with myelodysplastic syndromes (MDS), including lenalidomide (Revlimidâ) and the azanucleosides, azacitidine ... Efforts are also underway to improve the effectiveness of lenalidomide, a drug with preferential activity in the group of MDS patients ...

    Research Review last updated 05/02/2016 - 9:28am.

  3. Recent developments in myelodysplastic syndromes

    ... – 2006 ( azacitidine , decitabine , and lenalidomide ), none of these are curative.  In addition, no new drugs have ... with chromosome 5q deletions are more likely to respond to lenalidomide. -High-resolution genome-wide techniques can detect ...

    Research Review last updated 05/02/2016 - 9:16am.

  4. Infections in myelodysplastic syndromes: a review

    ... drugs (5-azacytidine and decitabine ) and lenalidomide in recent years for treating MDS has affected the natural ... age and neutropenia did not increase risk. Lenalidomide therapy can be a double-edged sword. While profound neutropenia ...

    Research Review last updated 05/02/2016 - 9:28am.

  5. Alan List, MD

    ... (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which ...

    Leadership Award last updated 05/02/2016 - 12:18pm.

  6. Pathogenesis of MDS: An overview of molecular and non-molecular aspects of the disease

    ... are currently three FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these ...

    Research Review last updated 05/02/2016 - 9:14am.

  7. Sexuality and Intimacy

    ... symptoms. Immunomodulatory agents like lenalidomide (Revlimid®) can cause fatigue, nausea and joint pain. ...

    Page last updated 05/02/2016 - 10:09am.

  8. Alan List, MD

    ... (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which ...

    Bio last updated 03/11/2016 - 1:41pm.

  9. Benjamin L. Ebert, MD, PhD

    ... Recent work has elucidated the mechanism of action of lenalidomide , a drug that acts by modulating the function of an ...

    Bio last updated 03/11/2016 - 1:41pm.

  10. Dr. Vivienne Rebel reviews a recent study about p53 protein levels as a prognostic factor in MDS

    ... enrolled in a randomized trial, for which they received lenalidomide or a placebo .  P53 staining was performed on samples ... overall survival and a lower cytogenetic response rate to lenalidomide treatment (i.e., the disappearance of cells with abnormal ...

    Research Review last updated 05/02/2016 - 9:17am.